← KT Medical Service PCL overview

KT Medical Service PCL vs Ramkhamhaeng Hospital: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

KT Medical Service PCL (KTMS.BK)

Q3 2026
▲3▼1

KTMS expands dialysis network; licensing delays shift revenue timing

  • Strong core dialysis growth and expansion KTMS's core hemodialysis revenue rose 9.34% in H1 2026 on more patients and new branches. It plans to add 3-5 units and 36-64 machines in H2, targeting 800 million baht revenue for 2026. This growth supports a higher share price.

    It shows the main business is growing and expanding, directly driving future revenue and profit.

  • High demand for dialysis services Thailand has about 8 million people at risk of kidney disease and 120,000 needing dialysis, with 80% choosing hemodialysis. KTMS's new branches already run at over 80% utilisation, showing strong demand that can lift future earnings.

    It explains the underlying demand that supports KTMS's expansion and revenue targets.

  • Licensing delays push back revenue Government licensing for new dialysis branches now takes about 120 days, up from 90 days. This delays when new branches can start earning money, so some revenue expected earlier may come later. It's a timing issue, not a loss of revenue.

    It is a real counterweight that could slow near-term revenue recognition and pressure the stock.

  • Q4 2026 outlook improves as branches open KTMS expects better Q4 2026 results as new branches gradually open and utilisation stays at least 80%. This suggests revenue will accelerate once licensing clears, supporting the stock.

    It gives a forward-looking positive catalyst that could drive the stock higher.

September 2026
▲3▼1

KTMS expands dialysis network; licensing delays shift revenue timing

  • Strong core dialysis growth and expansion KTMS's core hemodialysis revenue rose 9.34% in H1 2026 on more patients and new branches. It plans to add 3-5 units and 36-64 machines in H2, targeting 800 million baht revenue for 2026. This growth supports a higher share price.

    It shows the main business is growing and expanding, directly driving future revenue and profit.

  • High demand for dialysis services Thailand has about 8 million people at risk of kidney disease and 120,000 needing dialysis, with 80% choosing hemodialysis. KTMS's new branches already run at over 80% utilisation, showing strong demand that can lift future earnings.

    It explains the underlying demand that supports KTMS's expansion and revenue targets.

  • Licensing delays push back revenue Government licensing for new dialysis branches now takes about 120 days, up from 90 days. This delays when new branches can start earning money, so some revenue expected earlier may come later. It's a timing issue, not a loss of revenue.

    It is a real counterweight that could slow near-term revenue recognition and pressure the stock.

  • Q4 2026 outlook improves as branches open KTMS expects better Q4 2026 results as new branches gradually open and utilisation stays at least 80%. This suggests revenue will accelerate once licensing clears, supporting the stock.

    It gives a forward-looking positive catalyst that could drive the stock higher.

Latest
▲3▼1

KTMS expands dialysis network; licensing delays shift revenue timing

  • Strong core dialysis growth and expansion KTMS's core hemodialysis revenue rose 9.34% in H1 2026 on more patients and new branches. It plans to add 3-5 units and 36-64 machines in H2, targeting 800 million baht revenue for 2026. This growth supports a higher share price.

    It shows the main business is growing and expanding, directly driving future revenue and profit.

  • High demand for dialysis services Thailand has about 8 million people at risk of kidney disease and 120,000 needing dialysis, with 80% choosing hemodialysis. KTMS's new branches already run at over 80% utilisation, showing strong demand that can lift future earnings.

    It explains the underlying demand that supports KTMS's expansion and revenue targets.

  • Licensing delays push back revenue Government licensing for new dialysis branches now takes about 120 days, up from 90 days. This delays when new branches can start earning money, so some revenue expected earlier may come later. It's a timing issue, not a loss of revenue.

    It is a real counterweight that could slow near-term revenue recognition and pressure the stock.

  • Q4 2026 outlook improves as branches open KTMS expects better Q4 2026 results as new branches gradually open and utilisation stays at least 80%. This suggests revenue will accelerate once licensing clears, supporting the stock.

    It gives a forward-looking positive catalyst that could drive the stock higher.

Ramkhamhaeng Hospital Public Company Limited (RAM.BK)

Q3 2026
▲2▼1

RAM's profit jumps on hospital takeovers, but competition and weak demand weigh

  • RAM buys three hospitals, adds Khon Kaen Ram as subsidiary RAM spent 593 million baht to buy stakes in three hospitals, making Khon Kaen Ram a subsidiary. This means RAM can now include Khon Kaen Ram's revenue and profit in its own financial statements, boosting reported growth and expanding its hospital network.

    This is a major acquisition that directly boosts RAM's financials and growth story.

  • RAM's Q2 profit rises 29% on consolidating THG and CMH RAM reported Q2 2026 net profit of 345 million baht, up 29% from a year earlier, because it now includes the results of Thonburi Healthcare Group (THG) and Chiang Mai Ram (CMH) in its own accounts. Revenue more than doubled, though costs rose faster, so profit margin slipped.

    This is the actual earnings result that shows the impact of RAM's consolidation strategy.

  • Premium clinics in public hospitals intensify competition CGSI warns that new premium clinics in public hospitals are increasing competition for private hospitals like RAM, especially mid-tier ones. This could lead to price wars, higher marketing costs, and poaching of doctors. CGSI cut RAM's earnings estimates and target price but kept a hold rating.

    This is a key competitive threat that pressures RAM's pricing and profitability.

  • Weak domestic demand and Middle East conflict hurt, but recovery expected Analysts say hospital profits bottomed in Q2 2026 due to weak domestic spending and the US-Iran conflict reducing international patients. RAM is expected to recover in H2, with Q3 net profit likely up year-on-year, helped by a low base and the THG merger. However, competition and economic slowdown remain risks.

    This captures the overall sector trend and RAM's expected recovery, balancing negative and positive forces.

August 2026
▲2▼1

RAM's profit jumps on hospital takeovers, but competition and weak demand weigh

  • RAM buys three hospitals, adds Khon Kaen Ram as subsidiary RAM spent 593 million baht to buy stakes in three hospitals, making Khon Kaen Ram a subsidiary. This means RAM can now include Khon Kaen Ram's revenue and profit in its own financial statements, boosting reported growth and expanding its hospital network.

    This is a major acquisition that directly boosts RAM's financials and growth story.

  • RAM's Q2 profit rises 29% on consolidating THG and CMH RAM reported Q2 2026 net profit of 345 million baht, up 29% from a year earlier, because it now includes the results of Thonburi Healthcare Group (THG) and Chiang Mai Ram (CMH) in its own accounts. Revenue more than doubled, though costs rose faster, so profit margin slipped.

    This is the actual earnings result that shows the impact of RAM's consolidation strategy.

  • Premium clinics in public hospitals intensify competition CGSI warns that new premium clinics in public hospitals are increasing competition for private hospitals like RAM, especially mid-tier ones. This could lead to price wars, higher marketing costs, and poaching of doctors. CGSI cut RAM's earnings estimates and target price but kept a hold rating.

    This is a key competitive threat that pressures RAM's pricing and profitability.

  • Weak domestic demand and Middle East conflict hurt, but recovery expected Analysts say hospital profits bottomed in Q2 2026 due to weak domestic spending and the US-Iran conflict reducing international patients. RAM is expected to recover in H2, with Q3 net profit likely up year-on-year, helped by a low base and the THG merger. However, competition and economic slowdown remain risks.

    This captures the overall sector trend and RAM's expected recovery, balancing negative and positive forces.

Latest
▲2▼1

RAM's profit jumps on hospital takeovers, but competition and weak demand weigh

  • RAM buys three hospitals, adds Khon Kaen Ram as subsidiary RAM spent 593 million baht to buy stakes in three hospitals, making Khon Kaen Ram a subsidiary. This means RAM can now include Khon Kaen Ram's revenue and profit in its own financial statements, boosting reported growth and expanding its hospital network.

    This is a major acquisition that directly boosts RAM's financials and growth story.

  • RAM's Q2 profit rises 29% on consolidating THG and CMH RAM reported Q2 2026 net profit of 345 million baht, up 29% from a year earlier, because it now includes the results of Thonburi Healthcare Group (THG) and Chiang Mai Ram (CMH) in its own accounts. Revenue more than doubled, though costs rose faster, so profit margin slipped.

    This is the actual earnings result that shows the impact of RAM's consolidation strategy.

  • Premium clinics in public hospitals intensify competition CGSI warns that new premium clinics in public hospitals are increasing competition for private hospitals like RAM, especially mid-tier ones. This could lead to price wars, higher marketing costs, and poaching of doctors. CGSI cut RAM's earnings estimates and target price but kept a hold rating.

    This is a key competitive threat that pressures RAM's pricing and profitability.

  • Weak domestic demand and Middle East conflict hurt, but recovery expected Analysts say hospital profits bottomed in Q2 2026 due to weak domestic spending and the US-Iran conflict reducing international patients. RAM is expected to recover in H2, with Q3 net profit likely up year-on-year, helped by a low base and the THG merger. However, competition and economic slowdown remain risks.

    This captures the overall sector trend and RAM's expected recovery, balancing negative and positive forces.